Biofabrication of Autologous Human Hepatocytes for Transplantation: How Do We Get There?

Directed differentiation of hepatocytes from induced pluripotent stem cells (iPSCs) holds promise as source material for treating some liver disorders. The unlimited availability of perfectly differentiated iPSC-derived hepatocytes will dramatically facilitate cell therapies. While systems to manufa...

Full description

Saved in:
Bibliographic Details
Published in:Gene expression 2019-04, Vol.19 (2), p.89-95
Main Authors: Agarwal, Nandini, Popovic, Branimir, Martucci, Nicole J., Fraunhoffer, Nicolas A., Soto-Gutierrez, Alejandro
Format: Article
Language:English
Subjects:
Animals
Autografts
Cell Differentiation
Cell therapy
CRISPR
Extracellular matrix
Genes
Genomes
Growth factors
Hepatitis
Hepatocyte Proliferation
Hepatocytes
Hepatocytes - cytology
Hepatocytes - transplantation
Humans
Immunology
Induced Pluripotent Stem Cells - cytology
Liver
Liver diseases
Liver Diseases - therapy
Liver Regeneration
Liver transplantation
Metabolism
Patients
Pluripotency
Stem cells
Thinking Out Loud
Transplantation
Transplantation, Autologous
Transplants & implants
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Directed differentiation of hepatocytes from induced pluripotent stem cells (iPSCs) holds promise as source material for treating some liver disorders. The unlimited availability of perfectly differentiated iPSC-derived hepatocytes will dramatically facilitate cell therapies. While systems to manufacture large quantities of iPSC-derived cells have been developed, we have been unable to generate and maintain stable and mature adult liver cells ex vivo. This short review highlights important challenges and possible solutions to the current state of hepatocyte biofabrication for cellular therapies to treat liver diseases. Successful cell transplantation will require optimizing the best cell function, overcoming limitations to cell numbers and safety, as well as a number of other challenges. Collaboration among scientists, clinicians, and industry is critical for generating new autologous stem cell-based therapies to treat liver diseases.
ISSN:1052-2166
1555-3884
DOI:10.3727/105221618X15350366478989